Community-acquired pneumonia (CAP) is a common cause of morbidity and mortality in adults worldwide, but its epidemiology varies markedly by region. Whilst in high-income countries, the predominant burden of CAP is in the elderly and those with chronic cardiovascular and pulmonary co-morbidity, CAP patients in lowincome settings are often of working age and, in subSaharan Africa, frequently HIV-positive. Although region-specific aetiological data are limited, they are sufficient to highlight major trends: in high-burden settings, tuberculosis (TB) is a common cause of acute CAP; Gram-negative pathogens such as Klebsiella pneumoniae are regionally important; and HIV-associated opportunistic infections are common but difficult to diagnose. These differences in epidemiology and aetiological profile suggest that modified approaches to diagnosis, severity assessment and empirical antimicrobial therapy of CAP are necessary, but tailored individualized management approaches are constrained by limitations in the availability of radiological and laboratory diagnostic services, as well as medical expertise. The widespread introduction of the Xpert MTB/RIF platform represents a major advance for TB diagnosis, but innovations in rapid diagnostics for other opportunistic pathogens are urgently needed. Severity assessment tools (e.g. CURB65) that are used to guide early management decisions in CAP have not been widely validated in lowincome settings and locally adapted tools are required. The optimal approach to initial antimicrobial therapy choices such as the need to provide early empirical cover for atypical bacteria and TB remain poorly defined. Improvements in supportive care such as correcting hypoxaemia and intravenous fluid management represent opportunities for substantial reductions in mortality.
INTRODUCTION
Pneumonia is a common cause of morbidity and mortality in adults worldwide. Our understanding of pneumonia is however largely based on research from high-income Western countries. In these settings, the epidemiology of disease, the spectrum of causal pathogens and key prognostic factors are well characterized, and the approach to clinical management is standardized through national management guidelines. Clinicians in developing countries are left to decide whether the findings and recommendations are applicable in their local context. Is, for example, the spectrum pathogens identified in community-acquired pneumonia (CAP) patients in North America informative for selecting empirical antibacterial management in Niger? Does a CAP severity assessment tool developed in UK accurately predict outcome in Uganda? This narrative review summarizes data on the epidemiology and aetiology of CAP in developing countries, where available, giving priority to recent data, and considers how differences in disease within the broader healthcare context of resource limitations might impact upon the approach to diagnosis, assessment and management. The scope of the review is restricted to CAP in adults and it does not discuss the huge burden of childhood pneumonia that is present in many developing countries.
WHAT IS A DEVELOPING COUNTRY?
There is no universally accepted definition of what constitutes a developing country. The term has been used loosely and inconsistently to describe those countries with relatively poorer standards of living and economic prosperity. Until 2016, the World Bank classified all low-and middle-income countries (LMIC) as the developing world. 1 Whilst providing a convenient classification for analytical purposes, this 'developed' versus 'developing' dichotomy is outdated as economic growth in some developing countries accelerates rapidly and the developing world becomes increasingly dissimilar. The World Bank now groups countries into four strata based solely on gross national income. 1 The United Nations classification incorporates measures of human capital (e.g. under-five mortality and adult literacy) as well as economic indices. It identifies 48 least developed countries (LDC), defined as low-income countries with severe structural impediments to sustainable development. 2 The list includes all 31 lowincome economies defined by the World Bank with the exception of Zimbabwe: 34 are in sub-Saharan Africa with most others in Southeast Asia (e.g. Cambodia, Bangladesh and Laos). Whilst still diverse, LDC share many characteristics including high infant and underfive mortality, low adult life expectancy, food insecurity, incomplete access to electricity and limited healthcare expenditure. 2 Most LDC lie within tropical or subtropical regions. The global burden of HIV both in terms of numbers of people living with HIV and new HIV infections disproportionately affects sub-Saharan Africa. 3 Many LDC also face a high burden of tuberculosis (TB). 4 Detailed understanding of disease epidemiology within LDC is restricted by the paucity of available data. Therefore, whilst attempting to maximize use of data from LDC, this review includes relevant data from LMIC within sub-Saharan Africa and Southeast Asia. For convenience, the term low-income country has been used throughout.
PNEUMONIA EPIDEMIOLOGY: A GLOBAL PERSPECTIVE Incidence and risk factors
In high-income countries, increasing age is clearly the dominant risk factor for CAP. In the United States, overall incidence in adults is around 2.5 per 1000 person years, rising to 6.3 and 16.4 per 1000 person years in adults aged 65-79 and 80 years or older, respectively. 5 In low-income settings, population-level pneumonia incidence data are sparse, but the major burden of disease is highlighted by hospital registry data in which pneumonia is amongst the most common reasons for adult hospitalization. 6, 7 Interpretation of incidence data is often complicated by variations in the source (e.g. hospital registry and community surveillance), the case definition used and, if cause-specific, the extent of the microbiological evaluation. In a prospective surveillance study of adults in Central Vietnam, the incidence of all-cause CAP was estimated at 0.81 per 1000 person years, rising to 6.95 per 1000 person years in those aged 75 or older. 8 By comparison, the incidence of hospitalized pneumococcal pneumonia in a study from rural Thailand was relatively low: estimated at 0.31 and 1.5 per 1000 person years in all adults and those aged 70 or over, respectively. 9 In subSaharan Africa, the incidence of CAP is dominated by the effect of HIV which, if untreated, is associated with a 17-to 35-fold increase in pneumococcal pneumonia. 10, 11 In a community surveillance study in rural Kenya, the incidence of pneumococcal acute respiratory infection (defined as a respiratory symptom with fever, hypoxia or hospitalization) was estimated at 5 and 67 cases per 1000 person years in HIV-negative and -positive individuals, respectively. 12 In CAP cohorts from the region, HIV prevalence of 50-75% is typical. [13] [14] [15] [16] Malnutrition, household crowding and exposure to indoor air pollution from domestic combustion of biomass fuels may also contribute to the burden of pneumonia in low-income countries. 17, 18 Risk factors for CAP that are common in many high-income countries such as smoking, COPD, congestive heart failure and cerebrovascular disease 19 presumably pertain in lowincome settings and may become more prominent as average life expectancies increase.
The overall effect of alternative dominant drivers of CAP incidence acting upon markedly younger populations means that typical CAP patient encountered by clinicians differs markedly between high-and low-income settings. Whilst in the former, the predominant and increasing burden of hospitalized CAP is in the elderly and individuals with chronic cardiovascular or pulmonary co-morbidity, 20 a major burden of hospitalized CAP in many low-income countries is in working-age adults. 10 
Outcome
Globally, pneumonia is the most common infectious cause of death, the fourth most common cause of death overall and the second leading cause of life years lost. In 2015, the Global Burden of Disease Study estimated that lower respiratory tract infection (LRTI) caused 2 million adult deaths and an estimated 37 million years of loss life. 21 In high-income countries, nearly 90% of all LRTI deaths occur in adults over 70. By contrast, in sub-Saharan Africa, 46% of all LRTI deaths occur in children under 5 and amongst adults, 55% of deaths occur in those under 70, including 22% in adults aged 15-49 years. These marked differences in mortality burden may, in large part, reflect differences in population age distributions, but cause-specific, age-standardized mortality data are lacking. Amongst CAP cohorts from Africa, however, the typical trend of increasing mortality rates with advancing age seen in high-income settings is not consistently found. [14] [15] [16] 22 Within individual CAP cohorts, the observed mortality rate varies markedly with disease severity and treatment setting, ranging from <1% to nearly 50%. 23 Mortality in recently published cohorts from LDC were Cambodia, 23% 24 ; Central African Republic, 16% 24 ; Senegal, 19% 24 ; and Uganda, 18%. 25 Reported mortality rates from contemporaneous cohorts in high-income countries were Australia, 6% 26 ; Germany, 14% 20 ; and United States, 2%. 5 Differences in patient demographics, co-morbidity profile and clinical practice, particularly in terms of hospitalization rates, make meaningful comparisons of outcome between CAP cohorts difficult.
For example, in a recent US study of hospitalized CAP, inpatient mortality was 2% but 65% of patients were assessed to have low severity disease. 5 By comparison, in a national audit of 154 UK hospitals, average inpatient mortality was 17%, but the proportion with low severity disease was considerably lower at 40%. 27 Sow et al. recruited contemporary CAP cohorts in France and Guinea using an identical case definition that excluded patients with HIV and TB: despite being considerably older (mean age 62 years vs 38 years) and having a higher burden of co-morbid disease, mortality was not significantly higher in the French cohort (8% vs 6%). 28 In high-income countries, only around half of deaths that occur in the 3 months following an episode of CAP are directly attributable to pneumonia. 29 The risk of death in CAP patients remains elevated for at least 1 year compared with individuals hospitalized for other conditions, with much of the excess mortality risk being related to decompensation of underlying cardiovascular disease. 30 Neither the nature of mortality following CAP (i.e. pneumonia related or non-pneumonia related) nor the impact of CAP on long term survival is described in low-income countries.
PNEUMONIA AETIOLOGY
Initial antimicrobial therapy for CAP is almost always empirical; selecting an appropriate regimen therefore requires knowledge of the spectrum of organisms implicated in CAP locally. The differences in climate, geography and social conditions between high-income countries in temperate regions and low-income countries in tropical regions are likely to influence the prevailing aetiological profile of CAP. 31 
Streptococcus pneumoniae
For most low-income countries, Streptococcus pneumoniae is amongst the most common cause of CAP, typically identified in around one-quarter of all cases. 16, 32, 33 The true burden of disease may however be considerably higher as most aetiological studies employ only relatively insensitive diagnostic modalities (e.g. sputum Gram stain and culture). 34 Reduced in vitro susceptibility to both β-lactams and macrolides is widespread in S. pneumoniae isolates and very common in subSaharan Africa and Southeast Asia.
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Atypical bacterial pathogens
There are limited data on the burden so-called atypical bacterial infections (i.e. Legionella spp., Mycoplasma pneumoniae and Chlamydophila spp.) in low-income countries. Recent CAP cohorts from Kenya and South Africa identified legionellosis by commercial urinary antigen test in 9% and 2% of patients, respectively. 37, 38 Geographical variations in the prevailing species and serogroups of Legionella may reduce the effective sensitivity of urinary antigen testing which is specific for Legionella pneumophila serogroup 1. 39 In a recent CAP cohort from rural Thailand, legionellosis was identified in 5% of patients and all cases were caused by Legionella longbeachae. 40 The apparent burden of Mycoplasma and Chlamydophila infection depends on the diagnostic assays used. The few available African studies are largely based on serological assays (e.g. ELISA, immunofluorescence and complement fixation). 13, 16, 41 A high prevalence of M. pneumoniae with high rates of macrolide resistance has been observed in some middle-income Asian countries, 32 but data from low-income countries are lacking.
Gram-negative bacteria
The burden, spectrum and relative predominance of Gram-negative pathogens in CAP vary considerably by geographic region. Haemophilus influenzae remains a common cause of CAP and the prevalence of β-lactam resistance is increasing. 35 In South Africa and some Asian countries, Klebsiella pneumoniae is a common cause of severe bacteraemic CAP, displacing S. pneumoniae as the most common bacterial cause in some cohorts. 42, 43 Acinetobacter baumannii-typically associated with nosocomial pneumonia in high-income countries-has also been identified as a cause of severe CAP in tropical settings. 44 Burkholderia pseudomallei, the causative agent of melioidosis, is endemic in much of Southeast Asia, and commonly presents as an acute pneumonic illness. 45 
Tuberculosis
The global burden of TB rests disproportionately heavily on low-income countries. TB incidence in the World Health Organization (WHO) African and Southeast Asian regions is 275 and 246 cases per 100 000, respectively, and 86% of global TB deaths occur in these regions. 4 Whilst TB case finding programmes have largely focused on individuals with prolonged respiratory symptoms (usually cough for more than 2 weeks), 46 TB is a frequent cause of acute CAP in high-burden settings. In a prospective cohort from Cambodia, TB was the most common cause of acute pneumonia amongst older children and adults, accounting for a 26% of all radiographic pneumonia and 55% of cavitatory pneumonia. 33 Similarly, in subSaharan Africa, in CAP cohorts where systematic testing has been performed, up to 25% of all adult CAP is attributable to TB.
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Respiratory viruses
The increasing availability of sensitive molecular diagnostic tests has highlighted the high prevalence of respiratory viruses amongst CAP in high-income countries. 5, 26 Community surveillance of severe-acute respiratory illness in sub-Saharan Africa has demonstrated the high burden of circulating respiratory viral pathogens including influenza, rhinovirus, respiratory syncytial virus and adenovirus. 12 Influenza, in particular, is a common cause of hospitalized LRTI. 12 The seasonality that characterizes transmission in temperate climates is often not evident in tropical settings. The weak public health and diagnostic laboratory infrastructure, and the close proximity of human populations to animal reservoirs, present in many lowincome settings render them vulnerable to the emergence and propagation of novel respiratory pathogens.
PNEUMONIA IN THE CONTEXT OF HIV
Respiratory infections are a leading cause of morbidity and mortality in patients living with HIV. 47 The sequence of pulmonary complications of HIV infection parallels the depletion of CD4 cells. 48 Bacterial pneumonia and TB are common even when CD4 counts are well preserved whilst opportunistic infections, of which Pneumocystis jirovecii pneumonia (PCP) is most common, are generally only seen when CD4 counts decrease below 200 cells/mL. Most studies of HIVassociated respiratory infections have focused on specific aetiologies rather than systematically describing the full spectrum of pathogens and therefore there is no consensus on the optimal diagnostic algorithm. 47 In high-income settings, pneumonia in HIV-infected patients is usually regarded separately to CAP in other patients; management is individualized and there is often early recourse to invasive investigation. In highburden settings where up to three-quarters of all hospitalized CAP patients are HIV positive, the challenge for local CAP guidelines is to provide appropriate recommendations for this complicated group of patients using only basic diagnostic facilities.
The profile of HIV-associated pulmonary infections varies considerably by region. 47, 49 In high-income countries, bacterial infection, in particular S. pneumoniae, is the most common cause of CAP in HIV-positive adults overall, whilst PCP is the most common opportunistic infection in those with advanced disease. 50 Globally, TB is the most important HIV-associated opportunistic infection and is the leading cause of HIV-associated mortality. 4 Mycobacterium tuberculosis is frequently amongst the most commonly identified organism in CAP cohorts from sub-Saharan Africa and high TB burden settings in Southeast Asia. 13, 24, 33 In certain regions of South Africa, 42% of all hospitalized HIV-positive patients with cough have microbiologically confirmed TB. 51 Historically, the burden of PCP in low-income settings was thought to be low, 52 but recent bronchoscopy studies from African and Asian centres have reported PCP prevalence amongst HIV-infected patients with pneumonia of 18-44%. 22, 53, 54 Other less common causes of pneumonia may be regionally important. Invasive non-typhoidal Salmonella infection is the most common cause of bacteraemic illness in HIV-positive patients in sub-Saharan Africa and up to 10% present with an apparent pneumonic presentation. 55 Endemic fungi are common in HIV-infected patients living in high burden regions. 47 Penicillium marneffei, the causative agent of penicilliosis, is endemic throughout much of Southeast Asia and often presents as an acute severe pneumonic illness that is clinically indistinguishable from other causes of CAP. 31 Cryptococcosis and histoplasmosis also each account for more than 10% of acute pneumonic presentations in HIV-infected patients in endemic areas. 31, 56 Non-infective complications of HIV (e.g. pulmonary Kaposi's sarcoma) may masquerade as infections and should be considered in the differential diagnosis of acute pneumonic illnesses. 22, 47 HEALTHCARE SYSTEM CONTEXT CAP management guidelines developed in highincome countries assume levels of resource in terms of the availability of drugs, equipment, laboratory diagnostics and personnel that are absent in most lowincome settings. 57 In low-income countries, healthcare services are typically organized in a three-tiered system consisting of community health centres, district hospitals and regional central hospitals. In community facilities-where the majority of patients are managed-initial assessment is made by first-level healthcare workers who may, for example, not have been trained to perform chest auscultation. 58 Diagnostic tests are typically limited to point-of-care HIV and malaria antigens tests, and sputum smear microscopy for acid-fast bacilli (AFB). District hospitals are largely staffed by non-medically qualified general multipurpose practitioners such as clinical officers or senior nurses who may lack expertise in the management of complicated immunosuppressed patients. 58 Whilst usually available, chest radiography might be delayed or deliberately restricted for patients with clinical pneumonia who fail to respond to treatment. Specialist physician input and laboratory facilities for bacterial and mycobacterial culture and Pneumocystis diagnostics are often only available at regional or central hospitals. 58 Whilst the WHO list of essential medicines includes all of the antimicrobial agents commonly used to treat CAP in high-income settings, many healthcare facilities in low-income countries-particularly at community level-experience regular and prolonged stock outs. 59 Equipment for supportive management of patients is also often lacking or deficient. 57 Fewer than half of all healthcare facilities in sub-Saharan Africa have uninterrupted access to an oxygen source and one-quarter have no access at all. 60 Even where facilities and resources exist, however, transportation costs, user fees for diagnostics or treatment and loss of earnings for carers may impose substantial financial barriers that prevent equitable access to healthcare provision.
These constraints define the scope of clinical practice in low-income settings. Clinical management guidelines concerning initial assessment, aetiological diagnostics and therapeutic options all must be adapted accordingly. 58 
DIAGNOSIS AND ASSESSMENT
The three main components of the initial assessment of a patient presenting with suspected pneumonia are confirmation of the diagnosis of pneumonia, assessment of disease severity and identification of the causal pathogen. The approach taken to each of these tasks must be adapted in light of the differences in the profile of CAP and the available resources.
Defining and diagnosing pneumonia
The widely accepted diagnostic standard for pneumonia is the presence of a presumed new lung parenchymal infiltrate on a plain chest radiograph in the context of a compatible clinical presentation. 61, 62 Recent studies of computerized tomography scanning for patients presenting with suspected CAP have revealed the intrinsic limitations of plain chest radiography to accurately identify consolidation. 63 These limitations are accentuated for immunocompromised patients where the radiographical features of infection may be subtle or atypical. 64 Poor quality of film production coupled with interpretation by junior clinicians with limited radiological training may further compromise the accuracy of plain radiography.
On a practical level, chest radiography might not be immediately available in many low-income settings. Currently, WHO advocates a syndromic approach in community settings in which pneumonia is diagnosed on the basis of the combination of cough or breathing difficulties with two of fever, tachypnoea or chest pain are present. 58 The accuracy of this clinical case definition for radiographic pneumonia has not been systematically evaluated.
Thoracic ultrasound is an attractive alternative approach for pneumonia diagnosis well suited to use in resource-limited settings. Compared with conventional chest radiography, it does not require expensive radiation-proof facilities or a consistent supply of developer reagents. Portable, battery-operated devices suitable for use in community facilities with intermittent electrical power supply are available at increasingly affordable prices. With skilled operators, thoracic ultrasound has comparable specificity and superior sensitivity to chest radiography to detect lung consolidations. 65 Following focused training, the technique can be performed by non-specialist clinicians with reasonable accuracy. 66 Preliminary data also indicate potential utility in HIV populations. 67 Assessing disease severity CAP management guidelines from high-income countries recommend that management decisions about the setting of patient care and initial antimicrobial choice are based on an objective assessment of disease severity made using a validated tool. 61, 62 CAP severity assessment tools in current use have almost universally been derived in populations of non-immunocompromised patients in high-income settings. It should not be assumed that these tools perform accurately in CAP populations from low-income countries with very different demographic, co-morbidity and aetiological profiles.
The widely used CURB65 score estimates the risk of 30-day mortality in CAP patients based on the presence of confusion, urea >7 mmol/L, respiratory rate ≥30/ min, systolic blood pressure <90 mm Hg or diastolic blood pressure ≤60 mm Hg and age ≥65 years. The derivation cohorts from the UK, New Zealand and Netherlands, however, specifically excluded individuals with either HIV or confirmed TB. 68 CURB65 has been extensively validated in numerous high-income countries and has consistently shown good prognostic performance (area under the receiving operating characteristic curve (AUROC) of 0.80). 69 Its relative simplicity compared with other tools such as the pneumonia severity index (PSI) make it attractive for use in lowincome settings. However, the available studies of its accuracy in these populations yield mixed results. In a cohort of 280 HIV-infected CAP patients from South Africa, CURB65 score did not correlate with inhospital mortality for either all CAP overall or specifically pneumococcal pneumonia.
14 Similarly, CRB65 (the abbreviated version of CURB65 that does not require laboratory urea measurement) showed only moderate discriminate ability (AUROC: 0.65) for predicting in-patient mortality in a cohort of predominantly HIV-positive patients with clinically defined pneumonia in Malawi. 15 In a hospitalized CAP cohort from Pakistan, however, CURB65 performed accurately with an AUROC of 0.86. 70 Several studies have attempted to derive alternative locally adapted tools. In a cohort from Malawi, Birkhamshaw et al. derived the SWAT-Bp score (based on male sex, wasting, inability to stand, pyrexia/hypothermia and low blood pressure) that outperformed CRB65 for the prediction of in-patient mortality. 15 In a cohort of HIV-infected patients with suspected pneumonia in Uganda, Koss et al. derived a tool based on tachycardia, tachypnoea, hypoxaemia and low CD4 count. 25 Whilst neither of these novel tools has been adequately validated, these studies serve to indicate that there is considerable potential to improve disease severity assessment in low-income countries by using alternative tools.
Determining microbial aetiology General considerations
Initial antimicrobial therapy for CAP is almost invariably empirical. Determining the microbial aetiology of disease not only allows targeted therapy with the resultant benefits of optimized clinical efficacy and reduced promotion of antimicrobial resistance, but also provides valuable local surveillance data on the temporal trends in CAP pathogens. 61 CAP management guidelines in high-income countries recommend that both empirical antimicrobial therapy and the extent of investigation to determine microbial aetiology are based on severity assessment. 61, 62 Patients with severe disease initially receive the broadest spectrum treatment to cover all likely pathogens and in tandem undergo the most extensive investigation to maximize the chance of later targeting therapy. In reality, however, identifying the causal pathogen in CAP is challenging: even with extensive investigation in the context of research studies, it is only achieved in around 50%, and in clinical practice the proportion is much lower. 5, 26 The resource constraints of low-income settings demand that only investigations likely to result in a direct and substantial impact on patient management will be sustained. For example, the practical clinical value of a test to confirm pneumococcal aetiology is uncertain. All empirical CAP treatment regimens include antipneumococcal treatment and in lowincome settings with high HIV burden, a positive result would not necessarily remove the need for continued investigation to exclude co-infections. 71 The utility and cost-effectiveness of different diagnostic modalities will also vary by region and context. Whilst blood cultures are an expensive and usually fairly insensitive diagnostic modality in CAP, 61 in a Southeast Asian setting, for example, with high rates of bacteraemic Gram-negative disease, the facility might be valuable. 33, 43 Diagnostic tests for use in community-level facilities must require minimal staff training and laboratory infrastructure to perform. 72 As a complementary strategy to strengthening diagnostics at an individual patient-level, maintaining infection surveillance programmes based in centres that can support more extensive diagnostics (e.g. research facilities) may provide additional valuable information on local trends in prevailing pathogens to inform national treatment guidelines.
TB diagnostics
Until recently, the acute diagnosis of TB relied solely on smear microscopy and chest radiography. The singlemost important advance in TB diagnostics in recent years is the development of the automated Cepheid Xpert MTB/RIF (Cepheid, Sunnyvale, CA, USA) platform that can identify M. tuberculosis in an unprocessed sputum specimen in less than 2 h. With an overall sensitivity of 88% compared with sputum culture, it offers an incremental increase in sensitivity over smear microscopy of approximately 30%. 73 In a pragmatic clinical trial, Xpert MTB/RIF testing was used effectively by nurses in primary care healthcare facilities resulting in increased rates of same-day TB diagnosis and treatment initiation compared with a smear microscopy approach. 74 Trials of a new battery operated platform (GeneXpert Omni; Cepheid, Sunnyvale, CA, USA) using next-generation Xpert MTB/RIF Ultra cartridges (Cepheid, Sunnyvale, CA, USA) with reported sensitivity approaching that of TB culture are currently underway. 75, 76 New urine-based diagnostics may help to meet the challenge posed by patients with suspected TB who are unable to produce a sputum specimen. The TB Alere Determine TB LAM Ag (Alere Inc., Waltham, MA, USA) is a point-of-care test assay that detects the mycobacterial cell wall glycopeptide lipoarabinomannan (LAM) in urine. Whilst overall, its sensitivity for HIV-associated TB is only moderate (44%), it does provide improved diagnostic yield over sputum smear microscopy alone and is most sensitive in patients with severe disease at greatest risk of death (e.g. highly immunocompromised, anaemia and elevated C-reactive protein (CRP)). 77 
PCP diagnostics
Until recently, the definitive diagnosis of PCP required the microcscopic examination of bronchial lavage or induced sputum specimens for the direct visualization of Pneumocystis organisms. 78 The need for both bronchoscopy and an experienced microscopist precluded its use in many low-resource settings, hence the historically low-rate of reported PCP in low-income settings. 52 New molecular quantitative PCR tests have improved sensitivity such that analysis of more easily obtained upper respiratory tract specimens (e.g. oral wash and, nasopharyngeal aspirate) may be sufficiently accurate. 79 Recently developed assays that detect circulating fungal cell wall components (e.g. 1-3-β-D-glucan) in serum have shown excellent sensitivity for detecting PCP in patients with HIV. 80 However, neither of these two new modalities is as yet available in a format that could feasibly be applied in a resource-limited setting and new diagnostic options are urgently needed.
Alternative approaches to inferring aetiology CAP guidelines from high-income settings advise that neither clinical nor radiological features are sufficiently characteristic to distinguish between pneumonia caused by S. pneumoniae and atypical bacterial pathogens. 61 In low-income settings with high HIV burden, however, the pertinent clinical question is often to differentiate bacterial pneumonia from mycobacterial or Pneumocystis pneumonia. Clinical prediction tools based on radiological appearance (i.e. diffuse vs focal infiltrates and presence of mediastinal lymphadenopathy) and clinical features (i.e. presence of hypoxaemia) have been developed and form the basis of some treatment guidelines despite not being widely validated.
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Box 1: Distinctive characteristics of pneumonia in low-income settings Epidemiology and risk factors • Substantial burden of disease and associated mortality in working-age adults.
• HIV, malnutrition and indoor air pollution may predominate as locally important drivers of pneumonia incidence.
• In sub-Saharan Africa, in particular, pneumonia incidence dominated by effect of HIV: up to three-quarters of all hospitalized pneumonia patients are HIV-positive.
Aetiology
• TB accounts for up to one-quarter of acute pneumonia in high TB incidence settings in Southeast Asia and sub-Saharan Africa.
• Klebsiella pneumoniae is a common cause of severe bacteraemic pneumonia in Southeast Asia and South Africa.
• Pathogens not usually recognized as causes of CAP (e.g. Burkholderia pseudomallei, Penicillium marneffei and Histoplasma capsulatum) may account for a large proportion of acute pneumonic presentations within certain regions.
Clinical assessment
• Resource limitations may practically constrain approach to pneumonia diagnosis (e.g. limited access to chest radiography).
• CAP severity assessment tools derived in populations from well-resourced settings (e.g. CURB65) have not been extensively validated in low-income settings and may lack prognostic accuracy.
In practice, there is considerable overlap in the pattern of radiological features seen in patients with PCP and bacterial pneumonia. 82 In HIV, the radiographical features of TB become more variable with increasing degrees of immunocompromise. 83 Whilst standardized reporting tools and computer-aided systems both reduce the inter-observer variability of interpretation, the inherent limitations of the modality still apply. 84, 85 Depending upon the local epidemiology, Gramnegative pathogens may be an equally likely cause of cavitatory pneumonia as TB. 33 Inflammatory biomarkers (e.g. procalcitonin (PCT) and CRP) have been shown to distinguish bacterial from viral pathogens with reasonable accuracy in highincome settings and in children in sub-Saharan Africa. In adults with radiographic CAP, PCT levels in bacterial CAP are approximately 5 times higher that for TB and 19 times higher that for PCP. 50, 53 As yet, there are no data examining the ability of inflammatory biomarkers to safely define antimicrobial therapy in Africa.
ANTIMICROBIAL THERAPY
General considerations
Antimicrobial therapy for CAP is generally defined by national or regional guidelines. In resourced-limited settings, both the cost of the drug and the broader implications of the treatment regimen in terms of the impact of dosing frequency on nursing time need to be considered. As a common indication for antimicrobials, ecological impact and likelihood of promoting antimicrobial resistance should be considered. 35 Continued efforts to improve antimicrobial stewardship are needed: a recent survey from Vietnam found that intravenous (i.v.) antibiotics were used in 93% of hospitalized CAP patients regardless of the apparent severity of disease. 86 Fluoroquinolones have potent antituberculous activity and in high TB burden settings their empirical use may lead to both delayed diagnosis of TB and an increased risk of fluoroquinolone resistance. 87 
Severity-stratified antimicrobial selection
In high-income settings, antimicrobial selection is rationally stratified by disease severity and concordance with guidelines is associated with improved outcome. 88 In severe disease where the deleterious consequences of delayed appropriate treatment are potentially greatest, broad-spectrum therapy is used to give immediate cover for all probable pathogens including Legionella spp., Staphylococcus aureus, Gram-negative enteric bacteria and in some cases Pseudomonas. Adopting a similar approach in many low-income countries would present difficultiesparticularly in high HIV and TB burden settings-as empirical therapy for all probable pathogens would often have to be broadened to include cover for TB, PCP and, in some settings, drug resistant Gramnegative enteric bacteria and endemic mycoses. A 'step-up' approach is typically adopted, whereby nonresponse on broad-spectrum antibacterials prompts sequential addition of other agents, such as antimycobacterials and antifungals. This avoids the routine use of complex, expensive and potentially toxic treatments, but may miss the opportunity for early gains from aggressive therapy. 89 The WHO Integrated Management of Adolescent and Adult Illness (IMAI) guidelines were devised to provide general recommendations for disease management in low-income countries, particularly for clinicians working in community-or district-level healthcare facilities. 58 For severe pneumonia, IMAI guidelines recommend ceftriaxone plus a macrolide. 58 An aminoglycoside may be routinely added in regions with a high burden of CAP due to resistant Gram-negative pathogens. 81 For HIV-positive patients, high-dose cotrimoxazole for treatment of PCP is included for all patients, 58 although some national guidelines restrict empirical PCP treatment to patients with a suggestive chest radiograph or lack of clinical response at 48 h. 81 In high TB burden settings, the WHO approach to patients with severe CAP and negative AFB sputum smears is to first trial broad-spectrum antibacterials and if there is no improvement after 3-5 days, TB treatment is initiated. 46, 58 The optimal clinical indicators to define non-response are unclear. This approach misses 20% of patients with retrospectively culture-proven TB and risks delaying treatment in patients with a high risk of early death. 74 
SUPPORTIVE MANAGEMENT
Severe pneumonia is often complicated by sepsis-a dysregulated host response to infection resulting in organ dysfunction. The key components of sepsis management are adequate antimicrobial treatment, source control where relevant and supportive treatment. In high-income settings, a protocolized approach is typically used in which i.v. fluids are rapidly administered to correct abnormal physiology such as low blood pressure and is associated with reduced mortality. 90 In keeping with this approach, the WHO IMAI recommends early aggressive i.v. fluids to rapidly correct abnormal physiology, 58 but the only comparative trial of fluid resuscitation approaches in sepsis in a lowincome setting was stopped early due to high mortality. 91 Rapid fluid administration may be complicated by acute respiratory distress syndrome that in the absence of an intensive care unit may lead to an irretrievable deterioration. Further clinical trials are needed to determine whether an aggressive or conservative approach to i.v. fluid administration in sepsis in these settings is preferable.
Hypoxaemia is a common complication of pneumonia and is independently associated with mortality. 25 Supplemental oxygen provision in low-income settings is inadequate: fewer than half of healthcare facilities in sub-Saharan Africa have uninterrupted access to an oxygen source, 60 and in those that do demand invariably outstrips supply. 92 This is further compounded by the limited availability of pulse oximetry, such that the scant oxygen resources that are present may be inappropriately used in dyspnoeic but non-hypoxaemic patients. 93 In the absence of a piped-oxygen infrastructure, oxygen concentrators are often the mainstay of oxygen provision in many low-income settings; their effectiveness for correcting hypoxaemia in acutely ill adults has not been demonstrated. Whilst the use of non-invasive ventilation in CAP is not supported in high-income countries, 94 in settings where invasive ventilation is not available it is possible it might fill a niche role.
PNEUMONIA PREVENTION
Strategies for pneumonia prevention should also be adapted to the local disease profile to achieve maximal benefit. In high-income countries, pneumonia prevention strategies focus predominantly on pneumococcal and influenza vaccination of high-risk groups and smoking cessation. 61 Whilst pneumococcal conjugate vaccine (PCV) is known to be effective in HIV-positive patients, 95 it remains to be seen whether the significant reductions in vaccine-serotype pneumococcal disease observed in adults in high-income countries following the introduction of universal infant immunization with PCV are replicated in high HIV burden settings. 96 HIVinfected adults remain an important reservoir for carriage of pneumococci even after several years of antiretroviral therapy (ART) and apparent immune reconstitution. 97 ART, however, markedly reduces the risk of pneumonia in HIV-infected patients and early initiation improves survival. 11 The rapid roll-out of ART in sub-Saharan Africa has been a huge public health success with more than 12.1 million started on treatment, 3 but continued efforts are needed to minimize patient dropout at each stage of the care cascade from initially seeking HIV testing services to HIV diagnosis and linkage to ART programmes and then treatment initiation and continued adherence. 98 Cotrimoxazole preventative therapy continues to reduce the risk of hospitalization and pneumonia after ART initiation. 99 Isoniazid preventative therapy also provides an additive benefit over ART, reducing incident TB cases by as much as 43% in high-burden settings, 100 but to date has been widely underutilized in subSaharan Africa.
CONCLUSIONS
The approach to the assessment and management of CAP must be tailored to local settings. This review has highlighted that not only does CAP differ markedly between high-and low-income countries in terms of its epidemiology and aetiology (see Box 1), most notably with regard to the burdens of HIV and TB, but also in the healthcare system context in which it is managed. There is urgent need for improved access for basic medical equipment for supportive management and innovations in rapid diagnostics both to correctly diagnose pneumonia and to identify the aetiological agent. Further research is needed to address key knowledge gaps in disease severity assessment and region-specific aetiological patterns to inform optimal empirical treatment strategies with the potential for major reductions in mortality (see Box 2).
Box 2: Suggested research priorities in pneumonia in low-income settings Disease epidemiology and aetiology • Community surveillance studies to define the true incidence of pneumonia, particularly in potentially underserved groups (e.g. elderly).
• Sentinel surveillance programmes to monitor trends in aetiology (e.g. prevalence of Legionella spp., Mycoplasma pneumoniae and Chlamydophila spp., and spread of drug-resistant Gram-negative bacteria).
• In high HIV burden settings, define the prevalence of Pneumocystis jirovecii and other opportunistic pathogens (e.g. histoplasmosis) in acute CAP.
• Cohort studies to measure the impact of pneumonia on long-term morbidity (e.g. cardiovascular disease) and mortality (e.g. 1-year survival).
Clinical assessment
• Evaluate the accuracy of clinical case definitions of CAP suitable for use by community healthcare workers.
• Determine the accuracy and feasibility of clinician-performed thoracic ultrasound.
• Evaluate the use of computer-assisted chest radiograph interpretation to define early management based on pattern of radiological involvement.
• Develop locally validated severity assessment tools to predict early adverse outcome (e.g. mortality) and evaluate impact on early management decisions (e.g. site of care and antimicrobial choice).
• Develop and validate criteria of early clinical failure and response to guide treatment escalation or de-escalation.
Microbial diagnostics
• Evaluate routine, point-of-care use of Xpert MTB/RIF in CAP in high TB burden settings.
• Determine optimal approach to TB diagnosis in sputum-sparse CAP patients: urine lipoarabinomannan, urine Xpert MTB/RIF and computer-assisted radiography.
• In HIV patients, evaluate accuracy and feasibility of new P. jirovecii pneumonia (PCP) diagnostics based on blood (e.g. 1-3-β-D-glucan) and upper respiratory tract specimens (e.g. quantitative PCR).
Antimicrobial and supportive treatment
• Evaluate the safety of initial antimicrobial treatment selection based on locally validated clinical severity-assessment tools.
• Develop clinical trials to assess the safety and efficacy of extended empirical antimicrobial coverage in severe CAP of atypical bacteria and in HIV patients of PCP and possibly TB.
• Determine the most feasible and costeffective approach to expansion of supplemental oxygen provision.
